Answers are grounded in this paper and cite their sources.
A recent study used a monozygotic (MZ) twin design to investigate how the gut microbiome influences the severity of autism spectrum disorder (ASD) independent of genetic factors. By comparing genetically identical twins with discordant symptoms, the study identified the gut microbiome as a key non-shared environmental contributor. Beta-diversity analysis revealed distinct microbial community structures between high-severity and low-severity groups. Notably, the genus Porphyromonas , which is associated with inflammation and compromised gut barrier function, was enriched in high-severity twins. In contrast, these individuals exhibited reduced functional potential in pathways related to carbohydrate transport and amino acid metabolism. Collectively, these findings suggest that functional dysbiosis may exacerbate the symptoms of ASD via the gut-brain axis, potentially through systemic inflammation and altered metabolite production. While the MZ twin design effectively controls for genetic background, the study is limited by a small sample size and the absence of dietary data or mechanistic validation. Future research should employ multi-omics approaches and targeted interventions to confirm the regulatory chain of the gut microbiota metabolite-brain axis. Overall, the evidence suggests that while genetics provides the blueprint for ASD, the gut microbiome acts as a “dial” that modulates phenotypic severity.
No takes yet. Share an insight, caveat, or question.
Takahiko Nagamine (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: